Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing

Or Sehayek, Waleed Kian, Amir Onn, Ronen Stoff, Hadas Gantz Sorotsky, Melanie Zemel, Jair Bar, Yulia Dudnik, Hovav Nechushtan, Yakir Rottenberg, Lior Soussan-Gutman, Addie Dvir, Laila C. Roisman, Nir Peled*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Purpose: Molecular profiling is crucial in naïve non-small cell lung cancer (NSCLC). While tissue-based analysis is challenged by turnaround time and scarcity of tissue, there is increasing demand for liquid biopsy. We aimed to analyze the use of upfront liquid biopsy as a molecular profiling approach. Methods: This retrospective multicenter, non-interventional study compared findings and turnaround times of liquid vs. standard-of-care (SOC) tissue-biopsy molecular profiling. The study included naïve advanced NSCLC patients with available liquid biopsy (Guardant360 CDx). Results: A total of 42 consecutive patients (60% men; median age, 69.5 [39–87] years; 86% stage IV NSCLC) were identified between September 2017 and December 2020. Liquid-biopsy analysis provided results for all 42 patients, whereas the tissue-based analysis failed in 5 (12%) patients due to insufficient tumor samples. In 17 patients, 18 actionable driver mutations were identified. Eleven mutations were detected by both approaches (i.e., concordance of 61%), 4 only by liquid biopsy and 3 only by tissue biopsy. The median time from the molecular request to receiving the molecular solid report on the last biomarker was 21 (range: 5–66) days, whereas the median time from blood draw to the liquid-biopsy results was 10.5 (7–19) days. The median time between the availability of liquid-biopsy findings and that of the last biomarker was 5 days. Treatment changes following the liquid-biopsy results were observed in 3 (7%) patients. Conclusion: Performing liquid-biopsy upfront is feasible and accurate and allows a shorter time for treatment in NSCLC, especially when tumor tissue is scarce.

Original languageEnglish
Article number912801
JournalFrontiers in Oncology
StatePublished - 15 Jun 2022


FundersFunder number
Goldman Medical School
Rhenium-Oncotest, Ltd.


    • circulating tumor DNA (ctDNA)
    • driver mutation
    • liquid biopsy
    • non-small cell lung carcinoma (NSCLC)
    • turnaround time (TAT)


    Dive into the research topics of 'Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing'. Together they form a unique fingerprint.

    Cite this